<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368742</url>
  </required_header>
  <id_info>
    <org_study_id>GX1001</org_study_id>
    <nct_id>NCT03368742</nct_id>
  </id_info>
  <brief_title>Microdystrophin Gene Transfer Study in Adolescents and Children With DMD</brief_title>
  <acronym>IGNITE DMD</acronym>
  <official_title>A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solid Biosciences, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solid Biosciences, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a controlled, open-label, single-ascending dose study to evaluate the safety,&#xD;
      tolerability and efficacy of SGT-001 in adolescents and children with Duchenne muscular&#xD;
      dystrophy (DMD). Patients will receive a single intravenous (IV) infusion of SGT-001 and will&#xD;
      be followed for approximately 5 years.&#xD;
&#xD;
      The protocol was amended to drop the control arm after 4 subjects were dosed. Subjects&#xD;
      currently enrolling are assigned to active treatment. Control subjects enrolled under&#xD;
      original protocol will continue through the study per the original protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Active treatment group for all patients enrolled after June 2019. Total of approximately 16 to 32 patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in microdystrophin protein in muscle biopsies (active treatment group)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of clinical laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of abnormalities in vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of abnormalities in physical examinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of abnormalities on ECGs</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>SGT-001 - Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of SGT-001 at starting dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGT-001 - Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of SGT-001 at next ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated control group. After 1 year, treatment-eligible control patients will receive SGT-001 at the selected dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SGT-001</intervention_name>
    <description>AAV9 vector containing muscle-specific promoter and microdystrophin construct</description>
    <arm_group_label>SGT-001 - Dose Level 1</arm_group_label>
    <arm_group_label>SGT-001 - Dose Level 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Established clinical diagnosis of DMD and documented dystrophin gene mutation&#xD;
             predictive of DMD phenotype&#xD;
&#xD;
          -  Confirmed absence of dystrophin as determined by muscle biopsy (ambulatory patients)&#xD;
&#xD;
          -  Anti-AAV9 antibodies below protocol-specified thresholds&#xD;
&#xD;
          -  Stable cardiac and pulmonary function&#xD;
&#xD;
          -  Adolescents: non-ambulatory by protocol-specified criteria&#xD;
&#xD;
          -  Children: ambulatory by protocol-specified criteria&#xD;
&#xD;
          -  Stable daily dose (or equivalent) of oral corticosteroids ≥ 12 wks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or ongoing medical condition or physical examination, ECG or laboratory findings&#xD;
             that could adversely affect subject safety, compromise completion of treatment and&#xD;
             follow-up, or impair assessment of study results&#xD;
&#xD;
          -  Abnormal liver function&#xD;
&#xD;
          -  Abnormal renal function&#xD;
&#xD;
          -  Clinically significant coagulation abnormalities&#xD;
&#xD;
          -  Impaired cardiovascular function based on cardiac MRI or ECHO&#xD;
&#xD;
          -  Impaired respiratory function based on FVC % predicted or need for daytime ventilatory&#xD;
             support&#xD;
&#xD;
          -  Significant spinal deformity or presence of spinal rods&#xD;
&#xD;
          -  Body mass index ≥ 95th percentile for age&#xD;
&#xD;
          -  Exposure to another investigational drug within 3 months or 5 half-lives prior to&#xD;
             screening&#xD;
&#xD;
          -  Exposure to drugs affecting dystrophin or utrophin expression within 6 months prior to&#xD;
             screening&#xD;
&#xD;
        Additional inclusion/exclusion criteria may apply. Patients over 30 kg will not be eligible&#xD;
        for treatment at this time. A weight limit of ≤ 18 kg will be implemented for the next two&#xD;
        patients to be dosed.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roxana Donisa Dreghici, MD</last_name>
    <role>Study Director</role>
    <affiliation>Solid Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ummulwara Qasim</last_name>
      <phone>310-825-3264</phone>
      <email>UQasim@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Perry Shieh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Salabarria</last_name>
      <phone>352-273-6582</phone>
      <email>SGT001Inquiries@peds.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Barry Byrne, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ishita Tejani, MSPH, CCRP</last_name>
      <phone>312-227-3019</phone>
      <email>itejani@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Vamshi Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School-Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Figueira</last_name>
      <phone>508-856-1604</phone>
      <email>Sarah.Figueira@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Brenda Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

